1. Home
  2. NTRA vs PHM Comparison

NTRA vs PHM Comparison

Compare NTRA & PHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$244.06

Market Cap

27.0B

Sector

Health Care

ML Signal

HOLD

Logo PulteGroup Inc.

PHM

PulteGroup Inc.

HOLD

Current Price

$127.04

Market Cap

23.5B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTRA
PHM
Founded
2003
1950
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
27.0B
23.5B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
NTRA
PHM
Price
$244.06
$127.04
Analyst Decision
Strong Buy
Buy
Analyst Count
16
13
Target Price
$227.69
$134.31
AVG Volume (30 Days)
1.7M
1.7M
Earning Date
11-06-2025
10-21-2025
Dividend Yield
N/A
0.82%
EPS Growth
N/A
N/A
EPS
N/A
13.01
Revenue
$2,116,676,000.00
$17,622,999,000.00
Revenue This Year
$32.77
N/A
Revenue Next Year
$16.51
N/A
P/E Ratio
N/A
$9.76
Revenue Growth
38.17
1.76
52 Week Low
$125.38
$88.07
52 Week High
$245.59
$142.11

Technical Indicators

Market Signals
Indicator
NTRA
PHM
Relative Strength Index (RSI) 80.03 58.61
Support Level $233.67 $125.08
Resistance Level $240.18 $131.56
Average True Range (ATR) 7.39 3.17
MACD 0.68 1.19
Stochastic Oscillator 97.49 77.08

Price Performance

Historical Comparison
NTRA
PHM

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About PHM PulteGroup Inc.

PulteGroup Inc is a homebuilder in the United States. The company mainly builds single-family detached homes and offers products to entry-level, move-up, and active-adult buyers. It also offers homebuyers mortgage financing, title, and insurance agency services through its financial services segment.

Share on Social Networks: